Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy

Fig. 6

Soluble checkpoints and regulatory factors in plasma of BC patients compared to healthy controls. (A) Concentration of soluble factors (sCD27, sCD25) and soluble checkpoint molecules (sTIM-3, Galectin-9, sPD-1, sPD-L1 & 2, sLAG-3) were analyzed in plasma of cancer patients and healthy donors. Red symbols represent Luminal B breast cancer patients with HER2 over-expression. Data are given as mean ± SD (no significant differences were detected by one-way-ANOVA (Tukey’s multiple comparisons test). (B) Correlations of sLAG-3 and sTIM-3 to sPD-1 and between Galectin-9 and sTIM-3 of breast cancer patients (each entity represented by different color) are displayed. (C) Correlation of PD-L1 expression and secretion were determined. Correlation were determined using the two-tailed Pearson correlation test and p-values are indicated in each graph

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us